胃肠间质瘤治疗进展

胃肠间质瘤（GIST）是胃肠道最常见的间叶来源肿瘤。大部分患者存在c-kit或PDGFRa基因突变。手术根治性切除是治疗胃肠间质瘤的基石，但是术后复发率较高。近年来，以伊马替尼为代表的靶向治疗大大提高了GIST治疗效果。对于手术可以切除的患者，手术切除联合新辅助或辅助治疗改善了高危患者的预后：对于手术不可切除的患者，靶向治疗也有效地抑制、延缓了病情的进展。

Treatment progress of gastrointestinal stromal tumor

Gastrointestinal stromal tumor（GIST） is the most common mesenchymal tumor of the gastrointestinal tract. Its pathogenesis is defined by mutations within the KIT and PDGFRa gene. Surgical resection is the only radical treatment at present, but recurrence is common. In recent years, targeted therapy with imatinib mesylate, which inhibits KIT kinase activity, represents the other cornerstone for the treatment of GIST. For resectable GIST, operation combined with neoadjuvant and adjuvant therapy with imatinib mesylate or other tyrosine kinase inhibitors can improve the prognosis of high-risk patients before or after complete resection. For unresectable GIST, targeted therapy with imatinib mesylate can effectively inhibit and ameliorate the progression of GIST.